Efficacy and safety of transarterial chemoembolization plus lenvatinib in the treatment of advanced hepatocellular carcinoma: A meta-analysis

Article Oncology

Idarubicin-Loaded DEB-TACE plus Lenvatinib versus Lenvatinib for patients with advanced hepatocellular carcinoma: A propensity score-matching analysis

Wenzhe Fan et al.

Summary: Lenvatinib plus IDADEB-TACE is a well-tolerated and more effective treatment than lenvatinib monotherapy for patients with advanced HCC.

CANCER MEDICINE (2023)

Add to Collection

Review Oncology

Efficacy of Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombus: A Systematic Review and Meta-Analysis

Jia Deng et al.

Summary: TACE combined with TKIs can enhance the efficacy of treatment for hepatocellular carcinoma with portal vein tumor thrombus.

CURRENT ONCOLOGY (2023)

Add to Collection

Article Oncology

Objective Response by mRECIST to Initial Lenvatinib Therapy Is an Independent Factor Contributing to Deep Response in Hepatocellular Carcinoma Treated with Lenvatinib-Transcatheter Arterial Chemoembolization Sequential Therapy

Hidekatsu Kuroda et al.

Summary: This study compared the efficacy and safety of Lenvatinib-transcatheter arterial chemoembolization (LEN-TACE) sequential therapy to LEN monotherapy in patients with unresectable hepatocellular carcinoma (u-HCC). The results showed that the LEN-TACE group had significantly higher overall survival (OS) and progression-free survival (PFS) compared to the LEN monotherapy group. The initial response to LEN treatment was identified as an independent factor contributing to the deep response in LEN-TACE sequential therapy.

LIVER CANCER (2022)

Add to Collection

Article Oncology

Lenvatinib with or without Concurrent Drug-Eluting Beads Transarterial Chemoembolization in Patients with Unresectable, Advanced Hepatocellular Carcinoma: A Real-World, Multicenter, Retrospective Study

Dongdong Xia et al.

Summary: This study compared the clinical outcomes of lenvatinib plus DEB-TACE versus lenvatinib alone in treating HCC, demonstrating that the combination therapy was more effective in improving overall survival, progression-free survival, and objective response rate. Adverse events were mostly mild-to-moderate in both groups.

LIVER CANCER (2022)

Add to Collection

Article Oncology

Lenvatinib Combined With Transarterial Chemoembolization as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Phase III, Randomized Clinical Trial (LAUNCH)

Zhenwei Peng et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Review Oncology

Intraarterial Therapies for the Management of Hepatocellular Carcinoma

Tushar Garg et al.

Summary: Hepatocellular carcinoma is the most common liver cancer, and transarterial therapies play a crucial role in patient management. This article reviews the different types of transarterial therapies and discusses the pre-procedural, intra-procedural, and post-procedural patient management, along with a review of the literature.

CANCERS (2022)

Add to Collection

Review Oncology

Emerging Therapies for Hepatocellular Carcinoma (HCC)

Eesha Chakraborty et al.

Summary: Primary liver cancer is a major global health challenge with a significant negative impact on patient survival. Conventional cancer treatments are often ineffective due to the resistance of liver cancer. This review explores new and advanced therapies, such as gene therapy and immunotherapy, as potential breakthroughs for more effective and safer treatment.

CANCERS (2022)

Add to Collection

Article Oncology

Comparison of the Efficacy and Safety of Transarterial Chemoembolization with or without Lenvatinib for Unresectable Hepatocellular Carcinoma: A Retrospective Propensity Score-Matched Analysis

Yu-Xing Chen et al.

Summary: This study compared the safety and efficacy of TACE-lenvatinib with TACE alone for unresectable HCC patients. The results showed that TACE-lenvatinib group achieved better tumor control, PFS, and OS compared to the TACE group.

JOURNAL OF HEPATOCELLULAR CARCINOMA (2022)

Add to Collection

Article Pharmacology & Pharmacy

Efficacy of lenvatinib combined with sequential transarterial chemoembolization for primary hepatocellular carcinoma and the effects on serum basic fibroblast growth factor and vascular endothelial growth factor

Qing-Yun Xie et al.

Summary: This study investigated the therapeutic efficacy of lenvatinib combined with sequential TACE on primary HCC and its effects on serum bFGF and VEGF. The results showed that the combination treatment group had a higher objective response rate, lower serum bFGF and VEGF levels, and better survival rates.

FRONTIERS IN PHARMACOLOGY (2022)

Add to Collection

Review Oncology

Efficacy and safety of lenvatinib versus sorafenib in first-line treatment of advanced hepatocellular carcinoma: A meta-analysis

Jia Luo et al.

Summary: This meta-analysis compares the efficacy and safety of lenvatinib and sorafenib in patients with advanced hepatocellular carcinoma (HCC). The results showed that lenvatinib had significantly better progression-free survival and disease control rate compared to sorafenib, with similar incidences of adverse events. Lenvatinib is a promising alternative to sorafenib as a first-line therapy for advanced HCC.

FRONTIERS IN ONCOLOGY (2022)

Add to Collection

Article Gastroenterology & Hepatology

Lenvatinib versus Sorafenib as first-line treatment in hepatocellular carcinoma: A multi-institutional matched case-control study

Margherita Rimini et al.

Summary: Lenvatinib showed better performance compared to Sorafenib in a real-world setting, with more research needed to validate predictor factors for Lenvatinib response over Sorafenib.

HEPATOLOGY RESEARCH (2021)

Add to Collection

Article Oncology

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Hyuna Sung et al.

Summary: The global cancer burden in 2020 saw an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths. Female breast cancer surpassed lung cancer as the most commonly diagnosed cancer, while lung cancer remained the leading cause of cancer death. These trends are expected to rise in 2040, with transitioning countries experiencing a larger increase compared to transitioned countries due to demographic changes and risk factors associated with globalization and a growing economy. Efforts to improve cancer prevention measures and provision of cancer care in transitioning countries will be crucial for global cancer control.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

Add to Collection

Article Gastroenterology & Hepatology

Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma (uHCC): a retrospective controlled study

Zhigang Fu et al.

Summary: Combination treatment with TACE and lenvatinib shows significant improvement in clinical outcomes for unresectable HCC patients with manageable safety profile. The efficacy of this combination treatment should be further validated in prospective studies with larger sample size.

HEPATOLOGY INTERNATIONAL (2021)

Add to Collection

Article Oncology

Efficacy and Safety of Lenvatinib-Transcatheter Arterial Chemoembolization Sequential Therapy for Patients with Intermediate-Stage Hepatocellular Carcinoma

Yuwa Ando et al.

Summary: Sequential therapy of lenvatinib-transcatheter arterial chemoembolization (LEN-TACE) shows promising efficacy and safety in patients with intermediate-stage hepatocellular carcinoma, with significant impact on objective response rate (ORR) and progression-free survival (PFS).

ONCOLOGY (2021)

Add to Collection

Article Gastroenterology & Hepatology

Immunomodulatory Effects of Lenvatinib Plus Anti-Programmed Cell Death Protein 1 in Mice and Rationale for Patient Enrichment in Hepatocellular Carcinoma

Laura Torrens et al.

Summary: The combination treatment of lenvatinib and anti-PD1 showed tumor regression and faster response time in mouse HCC models. It significantly inhibited immune suppressive signaling and induced an immune-active microenvironment. Based on immune-related genomic profiles in human HCC, 22% of patients were identified as potential responders.

HEPATOLOGY (2021)

Add to Collection

Review Oncology